guaifenesin has been researched along with Alloxan Diabetes in 10 studies
Guaifenesin: An expectorant that also has some muscle relaxing action. It is used in many cough preparations.
| Excerpt | Relevance | Reference |
|---|---|---|
| " PC6/CS NPs efficiently enhanced the oral bioavailability of insulin to 16." | 1.56 | Thiolated Nanoparticles Overcome the Mucus Barrier and Epithelial Barrier for Oral Delivery of Insulin. ( Dai, W; Deng, H; He, B; Wang, X; Wu, P; Zhang, H; Zhang, Q; Zhang, Y; Zhao, R; Zhou, S, 2020) |
| " The aim of using PcCLs is to conquer the mucus and epithelium barriers, eventually improving the oral bioavailability of insulin." | 1.51 | Protein Corona Liposomes Achieve Efficient Oral Insulin Delivery by Overcoming Mucus and Epithelial Barriers. ( Fan, W; Gan, Y; Guo, S; Wang, A; Yang, T; Yang, Y; Yuan, Y; Zhang, T; Zhu, C; Zhu, Q, 2019) |
| " Further pharmacokinetic studies disclose an oral bioavailability of 15." | 1.48 | Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery. ( Fan, W; Gan, Y; Guo, S; He, S; Hovgaard, L; Li, X; Xia, D; Yang, M; Zhu, C; Zhu, Q, 2018) |
| "9-fold higher oral bioavailability was achieved compared with single CPP-modified P-R8 NPs on diabetic rats." | 1.48 | Biomimetic Viruslike and Charge Reversible Nanoparticles to Sequentially Overcome Mucus and Epithelial Barriers for Oral Insulin Delivery. ( Huang, Y; Liu, M; Shan, W; Wu, J; Zhang, Z; Zheng, Y, 2018) |
| " Moreover, in diabetic rats, pHPMA coated NPs generated a prominent hypoglycemic response following oral administration, and exhibited a relative bioavailability 2." | 1.43 | Efficient mucus permeation and tight junction opening by dissociable "mucus-inert" agent coated trimethyl chitosan nanoparticles for oral insulin delivery. ( Huang, Y; Li, L; Liu, M; Shan, W; Zhang, J; Zhang, Z; Zhong, J; Zhu, X, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 4 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kikuta, S | 1 |
| Kuboki, A | 1 |
| Yamasoba, T | 1 |
| Sintsova, O | 1 |
| Popkova, D | 1 |
| Kalinovskii, A | 1 |
| Rasin, A | 1 |
| Borozdina, N | 1 |
| Shaykhutdinova, E | 1 |
| Klimovich, A | 1 |
| Menshov, A | 1 |
| Kim, N | 1 |
| Anastyuk, S | 1 |
| Kusaykin, M | 1 |
| Dyachenko, I | 1 |
| Gladkikh, I | 1 |
| Leychenko, E | 1 |
| Zhou, S | 1 |
| Deng, H | 1 |
| Zhang, Y | 1 |
| Wu, P | 1 |
| He, B | 1 |
| Dai, W | 1 |
| Zhang, H | 1 |
| Zhang, Q | 1 |
| Zhao, R | 1 |
| Wang, X | 1 |
| Chen, Z | 1 |
| Han, S | 1 |
| Yang, X | 1 |
| Xu, L | 1 |
| Qi, H | 1 |
| Hao, G | 1 |
| Cao, J | 1 |
| Liang, Y | 1 |
| Ma, Q | 1 |
| Zhang, G | 1 |
| Sun, Y | 1 |
| Fan, W | 2 |
| Xia, D | 1 |
| Zhu, Q | 2 |
| Li, X | 1 |
| He, S | 1 |
| Zhu, C | 2 |
| Guo, S | 2 |
| Hovgaard, L | 1 |
| Yang, M | 1 |
| Gan, Y | 2 |
| Wu, J | 1 |
| Zheng, Y | 1 |
| Liu, M | 2 |
| Shan, W | 2 |
| Zhang, Z | 2 |
| Huang, Y | 2 |
| Wang, A | 1 |
| Yang, T | 1 |
| Yang, Y | 1 |
| Yuan, Y | 1 |
| Zhang, T | 1 |
| Zhang, J | 1 |
| Zhu, X | 1 |
| Li, L | 1 |
| Zhong, J | 1 |
| Lin, YC | 1 |
| Lu, MC | 1 |
| Tang, HL | 1 |
| Liu, HC | 1 |
| Chen, CH | 1 |
| Liu, KS | 1 |
| Lin, C | 1 |
| Chiou, CS | 1 |
| Chiang, MK | 1 |
| Chen, CM | 1 |
| Lai, YC | 1 |
| Nayak, AK | 1 |
| Pal, D | 1 |
| Pradhan, J | 1 |
| Hasnain, MS | 1 |
10 other studies available for guaifenesin and Alloxan Diabetes
| Article | Year |
|---|---|
Protective Effect of Insulin in Mouse Nasal Mucus Against Olfactory Epithelium Injury.
Topics: Animals; Diabetes Mellitus, Experimental; Insulin; Mice; Mucus; Olfactory Mucosa; Olfactory Receptor | 2021 |
Control of postprandial hyperglycemia by oral administration of the sea anemone mucus-derived α-amylase inhibitor (magnificamide).
Topics: Administration, Oral; alpha-Amylases; alpha-Glucosidases; Animals; Blood Glucose; Diabetes Mellitus, | 2023 |
Thiolated Nanoparticles Overcome the Mucus Barrier and Epithelial Barrier for Oral Delivery of Insulin.
Topics: Acrylic Resins; Administration, Oral; Animals; Biological Availability; Cell Line, Tumor; Chitosan; | 2020 |
Overcoming Multiple Absorption Barrier for Insulin Oral Delivery Using Multifunctional Nanoparticles Based on Chitosan Derivatives and Hyaluronic Acid.
Topics: Administration, Oral; Animals; Biological Transport; Caco-2 Cells; Cell Death; Chitosan; Diabetes Me | 2020 |
Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery.
Topics: Administration, Oral; Animals; Bile Acids and Salts; Biological Availability; Caco-2 Cells; Cardiova | 2018 |
Biomimetic Viruslike and Charge Reversible Nanoparticles to Sequentially Overcome Mucus and Epithelial Barriers for Oral Insulin Delivery.
Topics: Administration, Oral; Animals; Biomimetics; Caco-2 Cells; Diabetes Mellitus, Experimental; Drug Carr | 2018 |
Protein Corona Liposomes Achieve Efficient Oral Insulin Delivery by Overcoming Mucus and Epithelial Barriers.
Topics: Administration, Oral; Animals; Caco-2 Cells; Cations; Diabetes Mellitus, Experimental; Epithelial Ce | 2019 |
Efficient mucus permeation and tight junction opening by dissociable "mucus-inert" agent coated trimethyl chitosan nanoparticles for oral insulin delivery.
Topics: Acrylamides; Administration, Oral; Animals; Blood Glucose; Chitosan; Diabetes Mellitus, Experimental | 2016 |
Assessment of hypermucoviscosity as a virulence factor for experimental Klebsiella pneumoniae infections: comparative virulence analysis with hypermucoviscosity-negative strain.
Topics: Animals; Bacteremia; Bacterial Load; Diabetes Mellitus, Experimental; Humans; Klebsiella Infections; | 2011 |
Fenugreek seed mucilage-alginate mucoadhesive beads of metformin HCl: Design, optimization and evaluation.
Topics: Adhesiveness; Administration, Oral; Alginates; Animals; Blood Glucose; Chemistry, Pharmaceutical; Di | 2013 |